deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT01019616

Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

A Phase Ⅲ Study of Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

Sponsor: 307 Hospital of PLA

Conditions Primary Breast Cancer
Interventions paclitaxel/anthracycline
Updated 15 times since 2017 Last updated: Nov 26, 2021 Started: Mar 4, 2011 Primary completion: Jun 30, 2022 Completion: Jun 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Primary Breast Cancer and is currently ongoing. 307 Hospital of PLA leads this study, which shows 15 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Jan 2021 · 23 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2021 · 10 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Oct 2023 · 10 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  3. Dec 2023 — Jul 2024 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  4. Oct 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

▶ Show 10 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Unknown Status → Active Not Recruiting

  2. Feb 2021 — Dec 2021 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  3. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Feb 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Aug 2018 — Feb 2019 [monthly]

    Recruiting PHASE3

  6. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  7. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  8. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  9. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • 307 Hospital of PLA
  • Beijing Chao Yang Hospital
  • Beijing Municipal Science & Technology Commission
  • Chinese Academy of Medical Sciences
  • Peking Union Medical College Hospital
  • Peking University First Hospital
  • Peking University People's Hospital
  • Tao OUYANG
Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations